SeaStar Medical Holding Corporation (ICU) key performance indicators and operating metrics (7 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Net Product Revenue from Quell Immune Therapy | 497.5K | FY2026-Q1 |
| Neutralize Acute Kidney Injury Patients Enrolled To Date | 198.00 | FY2026-Q1 |
| Total Quell Immune Customer Base | 17.00 | FY2026-Q1 |
| SAVE Registry Enrollment (Patients Enrolled) | 50.00 | FY2026-Q1 |
| Pediatric Patients Treated in a Commercial Setting Under SAVE Surveillance Registry | 21.00 | FY2025-Q3 |
| Neutralize Acute Kidney Injury Additional Patients Enrolled During the Period | 21.00 | FY2025-Q3 |
| SAVE Surveillance Registry 28-Day Survival Rate | 75.00 percent | FY2025-Q3 |
Back to ICU overview · ICU earnings · ICU holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.